IMUC - ImmunoCellular Therapeutics Ltd(NYSEAMEX:IMUC)

legolego

Nuovo Utente
Registrato
22/2/10
Messaggi
2.900
Punti reazioni
39
Di questa IPO recente qualcuno sa qualcosa?...

Intanto..dal loro sito:

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company focused on developing novel immune-based products to treat cancer.
Our products and technologies are designed to harness the power of the immune system to improve the treatment of cancer. We are developing active immunotherapies that target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. Using our proprietary discovery technology, we also identify and develop monoclonal antibodies that may be used to treat a wide range of cancers. Our most advanced clinical programs are in glioblastoma multiforme (GBM). Our product candidates also have potential applications in other cancers with high unmet medical need.

Pipeline-Chart.gif


Our Technologies - ImmunoCellular Therapeutics, Ltd.
 
Di questa IPO recente qualcuno sa qualcosa?...

Intanto..dal loro sito:

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company focused on developing novel immune-based products to treat cancer.
Our products and technologies are designed to harness the power of the immune system to improve the treatment of cancer. We are developing active immunotherapies that target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. Using our proprietary discovery technology, we also identify and develop monoclonal antibodies that may be used to treat a wide range of cancers. Our most advanced clinical programs are in glioblastoma multiforme (GBM). Our product candidates also have potential applications in other cancers with high unmet medical need.

Pipeline-Chart.gif


Our Technologies - ImmunoCellular Therapeutics, Ltd.

Ciao, sul 107 sono attesi i dati sulla sicurezza, per fine anno quelli topline
 
Grazie delle info OK!

Al momento mi sembra "cara" per la pipeline che ha...
Ci sono altre bio dello stesso rango che hanno prodotti in fase 1 e 2 e che valgono la metà di questa che li ha quasi tutti in fase pre o 1
 
Volume: 2,772,876
Avg Vol (3m): 925,198

:eek:
 
Da qui... 6 Reasons ImmunoCellular Therapeutics Is One Of The Best Risk Vs. Rewards In The Market - Seeking Alpha

Valuation

In the last 12 months, analysts from three firms have put price targets on IMUC of $6, $6, and $18. With 75 million shares floated, a $6 share price makes IMUC a $450 million company, and an $18 share price makes IMUC a $1.35 billion company. The $10 average would make for a $750 million company, and that seems reasonable prior to results for ICT-107.

IMUC unquestionably has risks, but its upside is much higher than bringing ICT-107 to market. If ICT-140 shows efficacy in ovarian cancer, that would open up a market very similar to glioblastoma, and twice its size. Success in these programs would very likely mean that other tumors expressing these antigens could be successfully targeted as well. Additionally, the ICT-121 vaccine targeting the "universal" cancer stem cell antigen CD133 may have the most upside of all.

IMUC's platform has a real chance to break new ground in cancer therapy. While the platform is not a cure for cancer, it could prove to be a very effective therapy against minimal tissue recurrence in many cancers. Immunocellular Therapeutics' upside is very, very high. With encouraging results from the current phase IIb trial, IMUC could easily approach $9 billion.
 
After Hours: 3.61 +0.22 (6.49%)

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced financial results for the quarter ended June 30, 2013.

For the quarter ended June 30, 2013, the Company incurred a net loss of $150,000, or $0.00 per basic and diluted share compared to a net loss of $6.5 million for the quarter ended June 30, 2012, or $0.16 per basic and diluted share. The net loss for the quarter ended June 30, 2013 includes a gain of $2.0 million related to the change in fair value of the Company's warrants accounted for as derivatives and a charge of $180,000 in stock-based compensation. The net loss for the quarter ended June 30, 2012 includes a charge of $3.3 million related to the change in fair value of the Company's warrants accounted for as derivatives and $104,000 in stock-based compensation. For the six months ended June 30, 2013, the Company incurred a net loss of $5.1 million, or $0.10 per basic and diluted share, compared to a net loss of $14.3 million for the six months ended June 30, 2012, or $0.37 per basic and diluted share. The net loss for the six months ended June 30, 2013, reflects a charge of $604,000 related to the change in fair value of the Company's warrants accounted for as derivatives and $344,000 of stock based compensation. The net loss for the six months ended June 30, 2012 includes a charge of $7.8 million related to the change in fair value of the Company's warrants accounted for as derivatives and $349,000 of stock based compensation.

The Company reported that cash used in operations during the six months ended June 30, 2013 was $4.1 million compared to $6.9 million during the six months ended June 30, 2012. The decrease in cash usage was driven by a reduction in patient-related expenses in the phase II trial of ICT-107. This decrease was partially offset by certain preclinical expenses associated with ICT-140. During the six months ended June 30, 2013, the Company received $3.0 million from the exercise of warrants. As of June 30, 2013, the Company had $25.5 million in cash.

"We are pleased with the significant progress we have made in the first half of 2013 in advancing our cancer vaccine development pipeline, in our readiness planning efforts, and building the infrastructure, operational capabilities and financial resources we need to manage a growing and maturing development portfolio," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "We continue to be excited by the prospect of having three, novel, active clinical programs ongoing in the near-term. We believe that our cancer vaccine platform, including ICT-107, ICT-121 and ICT-140, as well as future pipeline programs, has the potential to transform the treatment of brain, ovarian and other cancers, and bring therapeutic benefit to patients and hope to their families. Our goal remains to build ImmunoCellular into a leading, independent commercial-stage cancer immunotherapy company."
 
Volumi nella media... :rolleyes:
Volume: 864,378
Avg Vol (3m): 968,175
 
in aumento :bow:

Volume: 1,008,769
Avg Vol (3m): 968,175
 
Volume: 2,681,526
Avg Vol (3m): 990,477

:eek:
 
:wall:
:wall:
 
Ultima modifica:
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) announced financial results for the quarter ended June 30, 2013.For the quarter ended June 30, 2013, the Company incurred a net loss of $150,000, or $0.00 per basic and diluted share compared to a net loss of $6.5 million for the quarter ended June 30, 2012, or $0.16 per basic and diluted share.

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) stock hit highest price at $2.89, beginning with a price of $2.89 and decreased -5.57% to the close at $2.71 with day range of $2.64 – $2.89. The total market capitalization of the stock is $147.95 million; total volume held in the session was 1.51 million shares which are lower than its average volume of 1.54 million shares.

:cool:
 
NEW YORK--(BUSINESS WIRE)--

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT: IMUC) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for an amendment of the Company’s 2006 Equity Incentive Plan.

Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on August 16, 2013, the Board of Directors recommends that ImmunoCellular’s shareholders vote to approve an amendment to the Company’s 2006 Equity Incentive Plan to increase the number of shares available for issuance thereunder from 8,000,000 to 12,000,000. The issuance of the additional shares could have a substantial dilutive effect on the shares of ImmunoCellular common stock.

Request more information now by clicking here: Faruqi & Faruqi LLP / Cases / SUMMARY. There is no cost or obligation to you.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.

If you own common stock in ImmunoCellular and wish to obtain additional information and protect your investments free of charge, please visit us at Faruqi & Faruqi LLP / Cases / SUMMARY or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (Faruqi & Faruqi LLP). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.

:eek:
 
:bow:

ImmunoCellular Therapeutics, Ltd. (IMUC)
-NYSE MKT

3.01 Up 0.26(9.45%)

Volume: 1,374,515
Avg Vol (3m): 1,112,410
 
sempre dentro... :rolleyes:

I believe that the recurrent glioblastoma market is currently about 2,000 patients and could represent an addressable market of $120 million or more in the US. Northwest Biotherapeutics (NWBO), ImmunoCellular (IMUC) and Celldex (CLDX) are each in Phase III or II programs in newly diagnosed glioblastoma and IMUC is beginning a Phase I trial in recurrent glioblastoma. This suggests that Agenus has a development lead in trials for recurrent glioblastoma, but is somewhat behind in newly diagnosed glioblastoma.
 
2.86 Down 0.18(5.92%)

mi ci vorra' una settimana per recuperare :wall:
 
Indietro